BioNexus Gene Lab Corp
NASDAQ:BGLC
BGLC's latest stock split occurred on Apr 7, 2025
The company executed a 1-for-10 stock split, meaning that for every 10 shares held, investors received 1 new share.
Before the split, BGLC traded at 0.235 per share. Afterward, the share price was about 2.92.
The adjusted shares began trading on Apr 7, 2025. This was BGLC's 2nd stock split, following the previous one in Jul 20, 2023.
1S9
BioNexus Gene Lab Corp
Glance View
BioNexus Gene Lab Corp. is a molecular diagnostics company, which focuses on the application of functional genomics to enable diagnosis and personalized health management. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan and currently employs 8 full-time employees. The company went IPO on 2020-03-11. The firm is focused on the application of functional genomics to enable early diagnosis and personalized health management. The firm's wholly owned subsidiaries include Bionexus Gene Lab Sdn. Bhd. (Bionexus Malaysia) and Chemrex Sdn. Bhd. (Chemrex). BioNexus Malaysia owns algorithm software, technology and know-how related to the detection of common diseases through blood analysis which it uses in its business. Its non-invasive blood screening tests analyze changes in ribonucleic acid (RNA) to detect the risk potentiality of approximately 11 different diseases. These diseases include cancers, bowel diseases and osteoarthritis. Chemrex is a wholesaler of industrial chemicals for the manufacture of industrial, medical, appliance, aero, automotive, mechanical and electronic industries in Asia Pacific region.
You don't have any saved screeners yet